• Mycobacterium tuberculosis and the response of its host
• 34 min
  1. The genetic structure of Mycobacterium tuberculosis - insights into genome organisation and evolution of the causative agent of tuberculosis

  • Dr. Roland Brosch
• 36 min
  2. The pathogenesis of tuberculosis

  • Dr. William R. Bishai
• 57 min
  3. Immune response and rational development of vaccines and biomarkers

  • Prof. Dr. Stefan H. E. Kaufmann
• 38 min
  4. Molecular mechanisms of drug resistance in M. tuberculosis

  • Dr. Daniela Cirillo
• The epidemiology of tuberculosis
• 40 min
  5. The basic epidemiology of tuberculosis (TB)

  • Dr. David Dowdy
• 34 min
  6. Global epidemiology of TB

  • Dr. Philippe Glaziou
• 48 min
  7. Social determinants of tuberculosis

  • Dr. Knut Lönnroth
• The control of tuberculosis
• 46 min
  8. Treatment of tuberculosis

  • Dr. Jean-Pierre Zellweger
• 32 min
  9. The End TB Strategy towards TB elimination 1

  • Dr. Mario Raviglione
• 52 min
  10. The End TB Strategy towards TB elimination 2

  • Dr. Mario Raviglione
• 38 min
  11. Financing TB care and control

  • Dr. Christopher Fitzpatrick
  • Dr. Andrea Pantoja
• 27 min
  12. Tuberculosis and COVID-19

  • Prof. Giovanni Battista Migliori
• 36 min
  13. Multidrug resistant tuberculosis (MDR-TB): an update

  • Dr. Simon Tiberi
• 49 min
  14. Impact of HIV on tuberculosis in the developing world and how to manage it

  • Prof. Anthony D. Harries
• 33 min
  15. Reaching the missing millions through public-private mix (PPM) for TB prevention and care

  • Ms. Hannah Monica Dias
• 39 min
  16. TB in children

  • Prof. Ben J. Marais
• 30 min
  17. Community engagement in tuberculosis care

  • Ms. Lana Syed
• 29 min
  18. India: the epicentre of global TB control

  • Dr. Madhukar Pai
• 23 min
  19. Community engagement in TB care

  • Dr. Haileyesus Getahun
• Research and development for new approaches in the control of tuberculosis
• 21 min
  20. Development of new regimens for tuberculosis

  • Dr. Zhenkun Ma
• 35 min
  21. Development, testing and introduction of new diagnostic tools for tuberculosis

  • Dr. Mark Perkins
• 69 min
  22. Pharmacometrics in tuberculosis

  • Prof. Charles A. Peloquin
• 29 min
  23. Extrapulmonary tuberculosis

  • Dr. Scott Heysell
• 27 min
  24. The role of surgery in tuberculosis management

  • Dr. Richard Zaleskis
• Archived Lectures *These may not cover the latest advances in the field
• 28 min
  25. The development of current treatments for tuberculosis

  • Dr. Andrew Nunn
• 47 min
  26. The pathogenesis of tuberculosis

  • Dr. William R. Bishai
• 34 min
  27. Basics of tuberculosis epidemiology

  • Prof. Frank Cobelens
• 40 min
  28. Drug resistance in tuberculosis and its public health management

  • Dr. Paul Nunn
• 57 min
  29. The international approach to the control of tuberculosis

  • Dr. Mario Raviglione
• 35 min
  30. Public-private mix for TB care and control

  • Dr. Mukund Uplekar

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. A very old disease
3. Outline
4. Discovery of streptomycin and the first RCT
5. The streptomycin trial: the 6 month results
6. The streptomycin trial: the 5 year results
7. Streptomycin and PAS
8. The acquisition of streptomycin resistance
9. Streptomycin, PAS and isoniazid
10. Changes in mortality from TB in the UK
11. From research to practice
12. MRC chronic trial
13. Results of the MRC chronic trial
14. The advent of short course chemotherapy
15. Short course chemotherapy: the first trial
16. First East African short course trial
17. How could these results best be compared?
18. The non inferiority design
19. Non-inferiority: first East African trial analysis
20. First East African short course study
21. The search for cheap but effective regimens
22. Treatment from 1972 to 2010
23. If 6 months works, why not 4?
24. Fourth East African short course
25. Trying again
26. Slow to adopt
27. Still waiting
28. Two unanswered questions
29. Treatment duration issues
30. Intermittent chemotherapy (1)
31. Intermittent chemotherapy (2)
32. New cases of tuberculosis in Zambia
33. Association between HIV and TB
34. Treatment duration issues for HIV coinfection (1)
35. Treatment duration issues for HIV coinfection (2)
36. The need for programmed based trials
37. Sahara study
38. Treating refugees in a war zone
39. The slow road to TB diagnosis
40. Smear negative disease
41. New regimens (the role of the mouse)
42. How do we choose the regimens to phase III?
43. MAMS (multi-arm multi-stage) trials
44. Phase III TB trials
45. The role of observational data
46. "A gulf which has been much underestimated"
47. East African and other drug resistance surveys
48. Kenya RCT programme results
49. Treating multidrug resistant TB
50. The STREAM trial
51. One drug - one shot in the dark?

Topics Covered

• Early trials demonstrated the need for giving more than one drug to avoid the problems of acquired drug resistance
• Short course chemotherapy highly effective provided rifampicin given throughout
• HIV coinfection has presented new challenges to effective treatment
• New methods needed to identify potential regimen candidates for phase III

Links

Series:

• Tuberculosis

Categories:

• Microbiology

Therapeutic Areas:

• Infectious Diseases
• Respiratory Diseases

Talk Citation

Publication History

• Published on February 28, 2013
• Archived on August 31, 2021

Financial Disclosures

• Dr. Andrew Nunn has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.